Vertex Pharmaceuticals Incorporated and bluebird bio would fund fertility preservation services for patients treated with their gene therapies for sickle cell disease under the Center for Medicare and Medicaid Services Innovation’s Medicaid payment demonstration if they choose to participate.
Key Takeaways
-
Vertex and bluebird bio will be allowed to pay for fertility preservation services for sickle cell disease patients who are administered gene therapy under the new CMMI demonstration, according to a request for proposals from the agency.
CMMI discussed fertility preservation and other aspects of manufacturer participation in its proposed Cell & Gene Therapy Access Model in...







